NCT02933307

Brief Summary

Rationale: Monitoring patients' vital signs is done to detect clinical deterioration. For this, the MEWS, a scoring list comprising seven vital signs measured by nursing staff, is used. Although the MEWS provides relevant data on patients' health status, the interval measurements may not capture early deterioration of vital signs, especially during the night. As a result, unsafe situations may occur such as periods of low oxygen saturation and cardiac arrhythmias, which are known to complicate postoperative course. Besides, this way of measuring vital signs may be stressful for patients and disturbs patients' sleep. New technology such as ViSi Mobile and HealthPatch allows for remote continuous monitoring of vital signs using wearable devices transmitting relevant data to nurses and clinicians. With this, the investigators think that clinical deterioration may be detected in an early phase and reduce nurse work load and patient distress. Objective: to investigate the feasibility of wearable devices on the general ward. Study design: feasibility study. Study population: adult patients hospitalized on the internal medicine ward and adult postoperative patients on the surgical ward. Intervention: patients in the intervention groups will be randomized in one of the two groups. Patients in the group 1 will wear ViSi Mobile; patients in group 2 will wear the HealthPatch. Wearable devices will be worn for at least three days. Regular MEWS measurements take place at usual time points. Main study parameters/endpoints: Evaluation with patient and care givers (primary outcome measure), MEWS calculations, time between alarm (continuous data) and next regular MEWS measurement (nurse), intervention by nurse after alarm, admission to ICU, complications, side effects of devices, STAI scores, and PCS scores will be documented. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will wear one device for at least three days. Devices can be uncomfortable by being heavy or the patches can start itching. More measurements by nurses can take place when indicated, for example after alarms. The participating patients will fill out the STAI on daily basis and the PCS on the last day of hospitalization. Both questionnaires will take a few minutes to complete. Patients could benefit from early detection of clinical deterioration and early corrective interventions or ICU admissions.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2015

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2015

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

July 25, 2016

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 14, 2016

Completed
Last Updated

April 25, 2017

Status Verified

July 1, 2016

Enrollment Period

1.3 years

First QC Date

July 25, 2016

Last Update Submit

April 24, 2017

Conditions

Outcome Measures

Primary Outcomes (2)

  • Expectations & experiences of patients

    Interviews of 15-20 minutes with patients after 2-3 days wearing a device or control group

    2-3 days after informed consent

  • Expectations & experiences of care givers

    Interviews with nurses of 15-20 minutes at the end of the study. Estimated amount of 6 nurses

    1 year

Secondary Outcomes (12)

  • MEWS scores based on continuous data and data measured by nurses

    3 times a day, up to three days.

  • Amount of alarms by HealthPatch or ViSi Mobile

    during 2-3 days when the patient wears a device

  • Time between alarm (continuous data) and next regular MEWS measurement (nurse)

    during 2-3 days when the patient wears a device

  • Amount of extra MEWS measurements by nurses due to alarms

    during 2-3 days when the patient wears a device

  • Admission to ICU (yes/no)

    during 2-3 days when the patient participates in this study

  • +7 more secondary outcomes

Other Outcomes (4)

  • Gender

    On day 1 when patients participates in the study

  • Age

    On day 1 when patients participates in the study

  • Diagnosis

    On day 1 when patients participates in the study

  • +1 more other outcomes

Study Arms (3)

Control group

NO INTERVENTION

Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))

HealthPatch (Intervention)

EXPERIMENTAL

Patients with HealthPatch and regular MEWS measurements

Device: HealthPatch

ViSi Mobile (Intervention)

EXPERIMENTAL

Patients with ViSi Mobile and regular MEWS measurements

Device: ViSi Mobile

Interventions

The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps

HealthPatch (Intervention)

ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.

ViSi Mobile (Intervention)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient is 18 years or older on the day the informed consent will be signed.
  • Patient is hospitalized on the surgical or internal medicine ward.
  • MEWS measurements are required at least three times a day.
  • Patient is able to speak, read and understand the local language of the investigational site, is familiar with the procedures of the study, and agrees to participate in the study program by giving oral and written informed consent prior to screening evaluations.

You may not qualify if:

  • Frequency of MEWS measurements is less than three times a day.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Weenk M, Bredie SJ, Koeneman M, Hesselink G, van Goor H, van de Belt TH. Continuous Monitoring of Vital Signs in the General Ward Using Wearable Devices: Randomized Controlled Trial. J Med Internet Res. 2020 Jun 10;22(6):e15471. doi: 10.2196/15471.

MeSH Terms

Conditions

Carcinoma, Pancreatic DuctalColorectal NeoplasmsArthritisHypertensionSepsis

Condition Hierarchy (Ancestors)

Carcinoma, DuctalAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, Ductal, Lobular, and MedullaryPancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesIntestinal NeoplasmsGastrointestinal NeoplasmsGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesJoint DiseasesMusculoskeletal DiseasesVascular DiseasesCardiovascular DiseasesInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Harry van Goor, MD, PhD, FRCS

    Radboud University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2016

First Posted

October 14, 2016

Study Start

April 1, 2015

Primary Completion

August 1, 2016

Study Completion

September 1, 2016

Last Updated

April 25, 2017

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will not share